TRIP13-a potential drug target in cancer pharmacotherapy
文献类型：期刊论文
| 作者 | Bunu, Samuel Jacob1,2; Cai, Haiyan3; Wu, Leyun1,2; Zhang, Hui3; Zhou, Zhaoyin; Xu, Zhijian1,2; Shi, Jumei3; Zhu, Weiliang1,2
|
| 刊名 | BIOORGANIC CHEMISTRY
 |
| 出版日期 | 2024-10-01 |
| 卷号 | 151页码:11 |
| 关键词 | AAA plus ATPase TRIP13 Cancer Drug target Small-molecule inhibitors |
| ISSN号 | 0045-2068 |
| DOI | 10.1016/j.bioorg.2024.107650 |
| 通讯作者 | Shi, Jumei(shijumei@tongji.edu.cn) ; Zhu, Weiliang(wlzhu@simm.ac.cn) |
| 英文摘要 | ATPases Associated with Diverse Cellular Activity (AAA+ATPases) are important enzymatic functional proteins in human cells. Thyroid Hormone Receptor Interacting Protein-13 (TRIP13) is a member of this protein superfamily, that partly regulates DNA repair pathways and spindle assembly checkpoints during mitosis. TRIP13 is reported as an oncogene involving multiple pathways in many human malignancies, including multiple myeloma, brain tumors, etc. The structure of TRIP13 reveals the mechanisms for ATP binding and how TRIP13 recognizes the Mitotic Arrest Deficiency-2 (MAD2) protein, with p31comet acting as an adapter protein. DCZ0415, TI17, DCZ5417, and DCZ5418 are the reported small-molecule inhibitors of TRIP13, which have been demonstrated to inhibit TRIP13 ' s biological functions significantly and effective in suppressing various types of malignant cells, indicating that TRIP13 is a significant anticancer drug target. Currently, no systematic reviews are cutting across the functions, structure, and novel inhibitors of TRIP13. This review provides a comprehensive overview of TRIP13 ' s biological functions, its roles in eighteen different cancers, four small molecule inhibitors, different underlying molecular mechanisms, and its functionality as a potential anticancer drug target. |
| WOS关键词 | RECEPTOR-INTERACTING PROTEIN ; POOR-PROGNOSIS ; PATHWAY CHOICE ; AAA-ATPASE ; CHECKPOINT ; PROGRESSION ; DRIVES ; TUMOR ; IDENTIFICATION ; PROLIFERATION |
| 资助项目 | National Key Research and Development Program of China[2022YFA1004304] ; National Natural Science Foundation of China[82273851] ; National Natural Science Foundation of China[82322067] ; National Natural Science Foundation of China[82170200] ; National Natural Science Foundation of China[81870158] ; Alliance of In-ternational Science Organization (ANSO) Scholarship for Young Talents[2022ANP10025] |
| WOS研究方向 | Biochemistry & Molecular Biology ; Chemistry |
| 语种 | 英语 |
| WOS记录号 | WOS:001277848400001 |
| 出版者 | ACADEMIC PRESS INC ELSEVIER SCIENCE |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/312562]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Shi, Jumei; Zhu, Weiliang |
| 作者单位 | 1.Univ Chinese Acad Sci, Sch Pharm, 19A Yuquan Rd, Beijing 100049, Peoples R China 2.Tongji Univ, Shanghai East Hosp, Dept Hematol, Sch Med, Shanghai 200120, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, State Key Lab Drug Res, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Bunu, Samuel Jacob,Cai, Haiyan,Wu, Leyun,et al. TRIP13-a potential drug target in cancer pharmacotherapy[J]. BIOORGANIC CHEMISTRY,2024,151:11. |
| APA | Bunu, Samuel Jacob.,Cai, Haiyan.,Wu, Leyun.,Zhang, Hui.,Zhou, Zhaoyin.,...&Zhu, Weiliang.(2024).TRIP13-a potential drug target in cancer pharmacotherapy.BIOORGANIC CHEMISTRY,151,11. |
| MLA | Bunu, Samuel Jacob,et al."TRIP13-a potential drug target in cancer pharmacotherapy".BIOORGANIC CHEMISTRY 151(2024):11. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。